Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

The CA19-9 and Sialyl-TRA Antigens Define Separate Subpopulations of Pancreatic Cancer Cells.

Barnett D, Liu Y, Partyka K, Huang Y, Tang H, Hostetter G, Brand RE, Singhi AD, Drake RR, Haab BB.

Sci Rep. 2017 Jun 22;7(1):4020. doi: 10.1038/s41598-017-04164-z.

2.

Expression and diagnostic value of HE4 in pancreatic adenocarcinoma.

Huang T, Jiang SW, Qin L, Senkowski C, Lyle C, Terry K, Brower S, Chen H, Glasgow W, Wei Y, Li J.

Int J Mol Sci. 2015 Jan 29;16(2):2956-70. doi: 10.3390/ijms16022956.

3.

High serum levels of DUPAN2 antigen and CA19-9 in pancreatic cancer: correlation with immunocytochemical localization of antigens in cancer cells.

Suzuki Y, Ichihara T, Nakao A, Sakamoto J, Takagi H, Nagura H.

Hepatogastroenterology. 1988 Jun;35(3):128-35.

PMID:
3042577
4.

Clinical evaluation of pancreatic cancer-associated mucin expressing CA19-9, CA50, Span-1, sialyl SSEA-1, and Dupan-2.

Kawa S, Kato M, Oguchi H, Hsue GL, Kobayashi T, Koiwai T, Tokoo M, Furuta S, Ichikawa T, Kanai M.

Scand J Gastroenterol. 1992 Aug;27(8):635-43.

PMID:
1359630
5.

Glycan motif profiling reveals plasma sialyl-lewis x elevations in pancreatic cancers that are negative for sialyl-lewis A.

Tang H, Singh S, Partyka K, Kletter D, Hsueh P, Yadav J, Ensink E, Bern M, Hostetter G, Hartman D, Huang Y, Brand RE, Haab BB.

Mol Cell Proteomics. 2015 May;14(5):1323-33. doi: 10.1074/mcp.M114.047837. Epub 2015 Mar 2.

6.

The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.

Staal B, Liu Y, Barnett D, Hsueh P, He Z, Gao C, Partyka K, Hurd MW, Singhi AD, Drake RR, Huang Y, Maitra A, Brand RE, Haab BB.

Clin Cancer Res. 2019 May 1;25(9):2745-2754. doi: 10.1158/1078-0432.CCR-18-3310. Epub 2019 Jan 7.

PMID:
30617132
7.

Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.

Dong D, Jia L, Zhang L, Ma N, Zhang A, Zhou Y, Ren L.

Cancer Sci. 2018 Sep;109(9):2841-2851. doi: 10.1111/cas.13712. Epub 2018 Jul 24.

8.

[Clinical usefulness of tumor markers associated with pancreatic cancer].

Watanabe H, Kawakami H, Yamakawa O, Satomura Y, Ohta H, Motoo Y, Okai T, Sawabu N.

Rinsho Byori. 1994 Feb;42(2):127-38. Review. Japanese.

PMID:
7908065
9.

Comparative study of CA-50 (time-resolved fluoroimmunoassay), Span-1, and CA19-9 in the diagnosis of pancreatic cancer.

Kobayashi T, Kawa S, Tokoo M, Oguchi H, Kiyosawa K, Furuta S, Kanai M, Homma T.

Scand J Gastroenterol. 1991 Jul;26(7):787-97.

PMID:
1896821
10.

[Evaluation of RCAS1 as serum tumor marker for pancreatic cancer].

Yang YC, Zhao YP, Liao Q, Zhang TP, Hu Y, Dai MH.

Zhonghua Wai Ke Za Zhi. 2009 Jul 1;47(13):999-1001. Chinese.

PMID:
19957811
11.

The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.

Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P.

Eur J Surg Oncol. 2005 Mar;31(2):164-9.

PMID:
15698733
12.

Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer.

Banfi G, Zerbi A, Pastori S, Parolini D, Di Carlo V, Bonini P.

Clin Chem. 1993 Mar;39(3):420-3.

13.

Immunohistochemical studies on the localization of cancer associated antigens DU-PAN-2 and CA19-9 in carcinomas of the digestive tract.

Ohshio G, Ogawa K, Kudo H, Yamabe H, Nakashima Y, Kim YC, Endo K, Watanabe Y, Manabe T, Tobe T.

J Gastroenterol Hepatol. 1990 Jan-Feb;5(1):25-31.

PMID:
2103381
14.

Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer.

Remmers N, Anderson JM, Linde EM, DiMaio DJ, Lazenby AJ, Wandall HH, Mandel U, Clausen H, Yu F, Hollingsworth MA.

Clin Cancer Res. 2013 Apr 15;19(8):1981-93. doi: 10.1158/1078-0432.CCR-12-2662. Epub 2013 Feb 27.

15.

Expression of various sialylated carbohydrate antigens in malignant and nonmalignant pancreatic tissues.

Satomura Y, Sawabu N, Takemori Y, Ohta H, Watanabe H, Okai T, Watanabe K, Matsuno H, Konishi F.

Pancreas. 1991 Jul;6(4):448-58.

PMID:
1678888
16.

CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis.

Gui JC, Yan WL, Liu XD.

Clin Exp Med. 2014 May;14(2):225-33. doi: 10.1007/s10238-013-0234-9. Epub 2013 Mar 3.

PMID:
23456571
17.

Serum concentration and immunohistochemical localization of SPan-1 antigen in pancreatic cancer. A comparison with CA19-9 antigen.

Takeda S, Nakao A, Ichihara T, Suzuki Y, Nonami T, Harada A, Koshikawa T, Takagi H.

Hepatogastroenterology. 1991 Apr;38(2):143-8.

PMID:
1855772
18.

Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype.

Kawa S, Oguchi H, Kobayashi T, Tokoo M, Furuta S, Kanai M, Homma T.

Br J Cancer. 1991 Nov;64(5):899-902.

19.

Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer.

Aldakkak M, Christians KK, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Evans DB, Tsai S.

HPB (Oxford). 2015 Oct;17(10):942-52. doi: 10.1111/hpb.12448. Epub 2015 Aug 10.

20.

CEACAM1, a novel serum biomarker for pancreatic cancer.

Simeone DM, Ji B, Banerjee M, Arumugam T, Li D, Anderson MA, Bamberger AM, Greenson J, Brand RE, Ramachandran V, Logsdon CD.

Pancreas. 2007 May;34(4):436-43.

PMID:
17446843

Supplemental Content

Support Center